# CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

> **NCT06449586** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 250 (estimated)

## Conditions studied

- Hematologic Malignancy

## Interventions

- **DRUG:** Letermovir

## Key facts

- **NCT ID:** NCT06449586
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06449586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06449586, "CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06449586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*